Filing Flows

Filing Flows › Companies › Integra Lifesciences Holdings › Cash flow

Integra Lifesciences Holdings cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$85.7M in Q3 2026 · $85.8M over twelve months

Operating cash flow$96.0M
Capital spending−$10.2M
Free cash flow+$85.7M
Cash / net income6.5×
Cash conversion cycle242 days

Analysis

In Q3 2026, Integra Lifesciences Holdings generated $96.0M of operating cash flow and spent $10.2M on capital projects, leaving free cash flow of $85.7M. That is $60.0M more than in Q3 2025 ($25.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $140M; the largest uses were capital spending ($54.6M), other investing ($48.7M), other financing ($6.5M); the cash balance rose by $20.1M.

Operating cash flow was $96.0M against net income of $14.9M — 6.5× profit, cash ran ahead of reported earnings. The largest differences: inventory +$24.1M, receivables +$18.0M, payables −$4.1M.

Its cash conversion cycle was 242 days (receivables 58 + inventory 219 − payables 34).

Free cash flow

Integra Lifesciences Holdings: free cash flow by quarterIntegra Lifesciences Holdings: free cash flow by quarter$21.1MQ4 2024−$40.2MQ1 2025−$11.2MQ2 2025$25.8MQ3 2025−$5.4MQ4 2025−$5.0MQ1 2026$10.5MQ2 2026$85.7MQ3 2026
Operating cash flow less capital spending.
Integra Lifesciences Holdings: operating cash flow against capital spendingIntegra Lifesciences Holdings: operating cash flow against capital spendingOperating cash flowCapital spending$50.7M$29.6MQ4 2024−$11.3M$28.9MQ1 2025$8.9M$20.1MQ2 2025$40.9M$15.2MQ3 2025$11.8M$17.2MQ4 2025$9.8M$14.8MQ1 2026$22.8M$12.3MQ2 2026$96.0M$10.2MQ3 2026
Latest (Q3 2026): Operating cash flow $96.0M, Capital spending $10.2M.

Capital allocation, year by year

Integra Lifesciences Holdings: where the cash came from (up) and went (down), by fiscal yearIntegra Lifesciences Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow $312MFY2021: Net borrowing −$100MFY2021: Shares issued $6.8MFY2021: Asset sales $190MFY2021: Capital spending −$48.0M$510MFY2021FY2022: Operating cash flow $264MFY2022: Net borrowing −$108MFY2022: Shares issued $5.5MFY2022: Asset sales $35.1MFY2022: Capital spending −$42.3MFY2022: Buybacks −$125M$305MFY2022FY2023: Operating cash flow $140MFY2023: Net borrowing $54.5MFY2023: Shares issued $4.3MFY2023: Capital spending −$66.9MFY2023: Buybacks −$275M$199MFY2023FY2024: Operating cash flow $129MFY2024: Net borrowing $299MFY2024: Shares issued $6.4MFY2024: Capital spending −$104MFY2024: Buybacks −$52.5M$435MFY2024FY2025: Operating cash flow $50.4MFY2025: Net borrowing $626MFY2025: Shares issued $957KFY2025: Capital spending −$81.4MFY2025: Buybacks −$221K$677MFY2025
Over these 5 years operating cash flow totalled $897M; the largest uses were buybacks ($453M) and capital spending ($343M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$312M
Debt$698M
Net debt$386M
Due within a year$38.8M

Integra Lifesciences Holdings funds itself: free cash flow was $85.8M over the last twelve months, and $312M of cash and investments stands against $698M of debt ($38.8M due within a year, 8.0× covered by cash).

Integra Lifesciences Holdings: debt maturities by year (FY2025)Integra Lifesciences Holdings: debt maturities by year (FY2025)$38.8MYear 1$53.3MYear 2$635MYear 3
Principal due in each year as disclosed in the annual report, against $312M of cash and investments now.

Where the cash came from and went

Integra Lifesciences Holdings: sources (+) and uses (−) of cash, Q3 2026Integra Lifesciences Holdings: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$96.0MNet borrowing (+) / repaid (−)−$46.1MCash drawn (+) / kept (−)−$37.8MCapital spending−$10.2MExchange rates−$1.6MTaxes on employees’ shares−$200K
Integra Lifesciences Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Integra Lifesciences Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$140MCapital spending−$54.6MOther investing−$48.7MCash drawn (+) / kept (−)−$20.1MOther financing−$6.5MNet borrowing (+) / repaid (−)−$6.0MExchange rates−$2.6MTaxes on employees’ shares−$1.9M

From profit to cash

Integra Lifesciences Holdings: net income to operating cash flow, Q3 2026Integra Lifesciences Holdings: net income to operating cash flow, Q3 2026Net income$14.9MStock-based pay$2.9MDeferred taxes$703KGains on disposals$1.5MReceivables$18.0MInventory$24.1MPayables−$4.1MDeferred revenue−$228KPrepaid and other assets−$1.3MOther liabilities−$1.0MOperating cash flow$96.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265821934242
Q2 20265822639244
Q1 20266225447269
Q4 20255721140228
Q3 20256322544244
Q2 20255920141219
Q1 20256220942229
Q4 20245420638222

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$96.0M−$10.2M—−$46.1M—−$37.8M$85.7M
Q2 2026$22.8M−$12.3M———$22.4M$10.5M
Q1 2026$9.8M−$14.8M—$8.9M—−$1.8M−$5.0M
Q4 2025$11.8M−$17.2M—$24.6M—−$2.9M−$5.4M
Q3 2025$40.9M−$15.2M—$565M—−$14.3M$25.8M
Q2 2025$8.9M−$20.1M—−$3.0M—$21.2M−$11.2M
Q1 2025−$11.3M−$28.9M—$39.2M$957K$7.3M−$40.2M
Q4 2024$50.7M−$29.6M−$2.5M−$4.5M—−$31.2M$21.1M

Integra Lifesciences Holdings: income statement and cash flow

Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%. The chart follows the revenue to costs, profit and cash.

Integra Lifesciences Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.